Smart Stocks Watch: Ampio Pharmaceuticals — Sexual Dysfunction, Ophthalmology, Nephrology

Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a clinical-stage biopharmaceutical company developing drugs for sexual dysfunction, inflammatory diseases and ophthalmological conditions has announced a manufacturing agreement with drug delivery maker Enthypharm Ltd for Zertane, Ampio’s drug for the treatment of premature ejaculation (PE).

Read more »

Smart Stocks Watch: Apricus Bio — Erectile Dysfunction, Anti-Fungals

The San Diego-based pharmaceutical company has five approved products internationally, covering erectile dysfunction (Vitaros), side effects of cancer therapy (Totect and Granisol), coronary artery disease (Nitromist) and dry mouth (Aquoral). After a series of successes in strategic partnerships, acquisitions, peer review and clinical data in Q3, the company is garnering some serious attention.

Read more »

Dr. Shi of EdgeTech Law: Genome Sequencing Could Soon Enter Mainstream

In Part III of our interview with Dr. Qin Shi of Edgetech Law we visit the concept of human genome sequencing as a mainstream commodity.

Read more »

Dr. Shi of EdgeTech Law: Emerging Opportunities in Life Sciences, Abroad

In Part II of our special interview series, Dr. Qin Shi of Edgetech Law discusses the emerging areas of significant unmet need in life science, and what investment opportunities may arise.

Read more »

Dr. Shi of EdgeTech Law: Despite Mayo Clinic v. Prometheus “Setback,” Opportunities in Life Sciences Remain

OneMedPlace is pleased to announce a special interview series exploring current issues facing the diagnostics sector and life sciences.

Read more »

Patent Infringement Special Report: Part III, the Future of Drug Development

Part Three of our Special Report analyzes what may be one of the first ‘test cases’ of the new patent infringement precedent.

Read more »

Patent Infringement Special Report: Part II, History and Precedent

Part two of our Special Report highlight an important case that may significantly affect the patent infringement landscape. Shares of Myriad Genetics fell 10 percent in the wake of the Mayo ruling.

Read more »

Patent Infringement Special Report: Part I, The Most Pressing Case

OneMedPlace is publishing a special in-depth look into the state of patent infringement in drug manufacturing.

Read more »